Kristin Chenoweth Kicks Off ‘Less Red, More You’ Campaign To Launch RHOFADE™ (Oxymetazoline HCL) Cream, 1%

As part of the campaign, Ms. Chenoweth, who suffers from rosacea, will ignite a nationwide conversation about the typically underserved condition while raising awareness for RHOFADE™ cream, a new product indicated for the topical treatment of persistent facial erythema associated with rosacea in adults.1

“As a performer who is constantly on stage or in front of the camera, it’s important that I take care of my skin, but unfortunately, persistent facial redness from rosacea is something I’ve struggled with every day for years,” said Chenoweth. “I’ve been searching for a product that, with daily use, can help keep my redness in check. Recently, my dermatologist recommended something new. She gave me RHOFADE™ cream, a treatment I use once-a-day, every day that helps reduce my redness all-day, through 12 hours so I see less red and more me.1 I’m thrilled to partner with Allergan to raise awareness for the persistent facial redness people with rosacea may deal with and RHOFADE™ cream. I hope that my experience can help make a difference for other sufferers who deal with this challenging condition every day.”

“Kristin is the perfect partner to help us increase awareness about this condition as she understands the daily challenges of living with rosacea,” said Jag Dosanjh, Senior Vice-President of Medical Dermatology at Allergan. “She is among the 16 million Americans who have rosacea, yet we know only a small fraction of that number is actually receiving treatment. Persistent facial redness is the most common sign of rosacea and is bothersome for patients, and now, RHOFADE™ cream can help patients take a step closer to achieving a more normal, healthy skin color.”1, 2,3

In two clinical trials, once-daily application of RHOFADE™ cream was proven to reduce persistent facial erythema associated with rosacea through 12 hours on day 29. Results seen in 12%–18% of people using RHOFADE™ cream vs 5%–9% of people using vehicle cream. The most common adverse reactions for RHOFADE™ were application site dermatitis, worsening inflammatory lesions of rosacea, application site pruritus, application site erythema, and application site pain.1

Patients who experience persistent facial redness should talk to their dermatologist about their condition. RHOFADE™ is currently available with a prescription. For more information, visit


RHOFADE™ (oxymetazoline hydrochloride) Cream 1% is indicated for the topical treatment of persistent facial erythema associated with rosacea in adults. 


Potential Impacts on Cardiovascular Disease 
Alpha-adrenergic agonists may impact blood pressure. RHOFADE™ should be used with caution in patients with severe or unstable or uncontrolled cardiovascular disease, orthostatic hypotension, and/or uncontrolled hypertension/hypotension. Advise patients with cardiovascular disease, orthostatic hypotension, and/or uncontrolled hypertension/hypotension to seek immediate medical care if their condition worsens.

Potentiation of Vascular Insufficiency 
RHOFADE™ should be used with caution in patients with cerebral or coronary insufficiency, Raynaud’s phenomenon, thromboangiitis obliterans, scleroderma, or Sjögren’s syndrome.  Advise patients to seek immediate medical care if signs and symptoms of potentiation of vascular insufficiency develop.

Risk of Angle Closure Glaucoma 
RHOFADE™ may increase the risk of angle closure glaucoma in patients with narrow-angle glaucoma. Advise patients to seek immediate medical care if signs and symptoms of acute angle closure glaucoma develop.


The most common adverse reactions for RHOFADETM were: application site dermatitis 2 %, worsening inflammatory lesions of rosacea 1%, application site pruritus 1%, application site erythema 1%, and application site pain 1%.

Please see RHOFADE™ full Prescribing Information.

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs currently in development.

Allergan’s success is powered by our more than 18,000 global colleagues’ commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan’s website at

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan’s current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan’s current expectations depending upon a number of factors affecting Allergan’s business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan’s products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan’s periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan’s Annual Report on Form 10-K for the year ended December 31, 2016 and Allergan’s Quarterly Report on Form 10-Q for the period ended March 31, 2017. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.


1. RHOFADE™ Prescribing Information, 2017. 
2. National Rosacea Society, If You Have Rosacea, You’re Not Alone, Nationals Rosacea Society website, Accessed March 1, 2017. 
3. National Rosacea Society, All About Rosacea. National Rosacea Society website, Accessed March 1, 2017.

© 2017 Allergan. All rights reserved. All trademarks are the property of their respective owners.


Daphne Karydas 
(862) 261-8006

Mark Marmur 
(862) 261-7558


Ember Garrett 
(714) 246-3525